Osimertinib Approved for First-Line Treatment in Metastatic NSCLC

被引：0
|
作者：
Schuyler, Devon
机构：
来源：
CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY | 2018年 / 16卷 / 06期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：397 / 397
页数：1
相关论文
共 50 条
  • [21] TAPO in first-line osimertinib therapy and continuation of osimertinib
    Mimura, Chihiro
    Kaneshiro, Kazumi
    Fujimoto, Shodai
    Dokuni, Ryota
    Iwamoto, Natsuhiko
    Matsumura, Kanoko
    Hatakeyama, Yukihisa
    Kono, Yuko
    Tachihara, Motoko
    THORACIC CANCER, 2023, 14 (06) : 584 - 591
  • [22] Osimertinib Approved for Use in NSCLC
    Schuyler, Devon
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2015, 13 (12) : 876 - 876
  • [23] Gencitabine and carboplatin as first-line therapy in advanced/metastatic NSCLC
    Savio, G.
    Laudani, A.
    Usset, A.
    Leonardi, V.
    Pepe, A.
    Palmisano, V.
    Agostara, B.
    ANNALS OF ONCOLOGY, 2005, 16 : 24 - 25
  • [24] RET plus advanced NSCLC RET Inhibitor approved for First-Line Use
    Freye, Reimund
    ACTA HAEMATOLOGICA, 2022, 145 (02) : 232 - 232
  • [25] RET plus advanced NSCLC RET Inhibitor approved for First-line Use
    Freye, Reimund
    ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (1-2) : 73 - 73
  • [26] Safety of tepotinib plus osimertinib in EGFR-mutant NSCLC with MET amplification after first-line osimertinib
    Liam, C. K.
    Kim, T. M.
    Yang, J-J.
    Huang, C.
    Voon, P-J.
    Tho, L. M.
    Zhou, Q.
    Wang, J.
    Hayashi, H.
    Tan, D. S. W.
    Danchaivijitr, P.
    Nguyen, V. N.
    Wong, K. H.
    Yang, J. C-H.
    Le, X.
    Ellers-Lenz, B.
    Karachaliou, N.
    Ghori, V.
    Berghoff, K.
    Wu, Y-L.
    ANNALS OF ONCOLOGY, 2023, 34 : S1691 - S1691
  • [27] BUDGET IMPACT OF AFATINIB VS OSIMERTINIB IN FIRST-LINE TREATMENT OF EGFR COMMON MUTATION POSITIVE NSCLC IN CHINA
    Yan, J. Z.
    Gong, X. L.
    Zhao, J.
    Shao, R.
    Zhang, Y. J.
    Hong, G.
    Xue, N.
    Mu, S.
    VALUE IN HEALTH, 2020, 23 : S49 - S49
  • [28] Treatment Patterns and Clinical Outcomes in Patients with EGFR-mutant NSCLC after Progression on First-Line Osimertinib
    Robinson, N. D.
    Zhan, P.
    Udelsman, B.
    Boffa, D. J.
    Goldberg, S. B.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S364 - S364
  • [29] Combination of Osimertinib and Bevacizumab as First-line Treatment for Patients With Metastatic EGFR-Mutant Lung Cancers
    Qi, Chuang
    Cui, Huanxi
    Chen, Dongsheng
    JAMA ONCOLOGY, 2020, 6 (12)
  • [30] Real-World Data of Osimertinib in Patients with Metastatic EGFRm plus NSCLC who Progressed on First-Line EGFR TKIs
    Ma, J.
    Tan, S. H.
    Yin, D.
    Tran, A.
    Tan, D.
    Ang, M.
    Takano, A.
    Lim, K. H. T.
    Kanesvaran, R.
    Jain, A.
    Rajasekaran, T.
    Tan, E.
    Lim, D. W.
    Ng, Q. S.
    Tan, W.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S627 - S628
12345